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Abstract 
With advances in brain imaging and completion of randomized clinical trials (RCTs) for 
primary and secondary stroke prevention, the natural history of central nervous system 
(CNS) complications in sickle cell disease (SCD) is evolving. In order of current 
prevalence the primary CNS complications include silent cerebral infarcts (39% by 18 
years), headache (both acute and chronic: 36% in children with sickle cell anemia 
(SCA), ischemic stroke (as low as 1% in children with SCA with effective screening and 
prophylaxis, but ~11% in children with SCA without screening) and hemorrhagic stroke 
in children and adults with SCA, 3% and 10%, respectively.  In high income countries 
RCTs (STOP, STOP II) have demonstrated that regular blood transfusion therapy 
(typically monthly) achieves primary stroke prevention in children with SCA and high 
transcranial Doppler (TCD) velocities; after at least a year, hydroxycarbamide may be 
substituted (TWiTCH). Also in high income countries, RCTs have demonstrated that 
regular blood transfusion is the optimal current therapy for secondary prevention of 
infarcts for children with SCA and strokes (SWiTCH), or silent cerebral infarcts (SIT). For 
adults with SCD, CNS complications continue to be a major cause of morbidity and 
mortality, with no evidence-based strategy for prevention. 
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Introduction 
With recent advances in medical treatment, the natural history of sickle cell disease 
(SCD) continues to evolve as morbidity and mortality fall. In the last 40 years 
significant clinical research efforts have been focused on preventing initial and 
subsequent central nervous system (CNS) injuries.  In children and adults with SCD, 
from the 1970s until 2010, approximately 75% of the infarcts were ischemic and the 
remainder hemorrhagic.1,2  In the 1990s , the prevalence of  the first transient 
ischemic attack, infarctive or hemorrhagic stroke in children with SCA younger than 
19 years was 11%3 and 24% by 45 years for adults with SCA.3  Since the 1990s, four 
major randomized trials to prevent CNS injuries have been completed providing 
evidence based guidelines for primary and secondary stroke prevention in children 
with SCA.4-8   
 
Unfortunately in sub-Saharan African countries and India, where greater than 90% of 
the children with SCA are born9, there are no evidence based primary and secondary 
stroke prevention strategies. Thus before their 18th birthday, approximately 50% of the 
children with SCA will have either an overt or silent cerebral infarct (SCI), Figure 1.  
 
The pathophysiology of ischemic stroke and cerebral hemorrhage in SCD is not well 
defined10 but over the last three decades, we have begun to understand more about 
clinical risk factors and potential mechanisms of brain injury, Figure 2.  At least six risk 
factors are associated with cerebral ischemic events in SCD:  
1. low oxygen content  associated with  
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a. lower oxygen saturation11,12 or  
b. acute drop in hemoglobin13,14  
2. presence of cerebral vasculopathy compromising cerebral blood flow (CBF), acting 
synergistically with the compensatory increase in CBF secondary to  
a. anemia and 
b. increased percentage of hemoglobin S  to decrease cerebrovascular 
reserve. The substantial impact on hemoglobin S levels on CBF is a unique 
attribute of SCD and must be considered in acute management of strokes 
when the goal is to rapidly lower hemoglobin S levels, Figure 315  
3. acute infection with fever 14 increasing cerebral metabolic demands, 
4. cardiovascular risk factors as in the general population: hypertension, diabetes 
mellitus, hyperlipidemia, atrial fibrillation, and renal disease, the last four in adults 
with SCD only2  
5. presence of a prior cerebral infarct with the greatest risk being within two to three 
years of infarct occurrence, regardless of treatment1,13  
6. rapid increases in hemoglobin levels typically greater than 12 g/dl with either auto-
transfusion from splenic or liver sequestration 16 or blood transfusion therapy.17 
 
Adults with SCD have different risk factors for strokes and different prevalence of 
ischemic and hemorrhagic stroke than children with SCD. In a large population study, 
the biggest risk factor for strokes in children with SCD was hypertension; whereas, in 
adults with SCD, the biggest risk factors included not only hypertension, but also 
diabetes mellitus, hyperlipidemia, atrial fibrillation, and renal disease.18 The 
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determinants of cognition in adults with SCD are not well documented. In 
asymptomatic adults with SCA undergoing cognitive testing, performance IQ was not 
associated with sex, white blood cell count, platelet count, or levels of hemoglobin F, 
lactate dehydrogenase, or hemoglobin levels.19 This review will initially focus on the 
epidemiology of the most common CNS complications, primarily in SCA, and then will 
review the evidence for primary and secondary stroke prevention in high and low 
income countries. 
 
Silent Cerebral Infarcts Are Common in SCA 
SCI is the most common permanent neurological injury in children with SCA, and 
probably in adults as well. The only current strategy to detect a SCI is a 30-60 minute 
brain image with magnetic resonance image (MRI). The most complete definition of a 
SCI has both a neuroimaging component and an assessment by a neurologist.7 The 
imaging component requires a signal abnormality that is at least 3 mm in one 
dimension and that is visible in two planes on fluid-attenuated inversion recovery 
(FLAIR) T2-weighted images. The neurology component includes a normal 
neurological examination or an abnormality on examination that could not be 
explained by the location of the brain lesion or lesions.7 The neurological evaluation by 
a neurologist is critical because individuals that are previously labeled as having a SCI 
may in fact have an undetected stroke, a higher risk category for future neurological 
morbidity.20  
 
SCIs are common in infants and pre-school children. Approximately 25% of children 
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with SCA will have an infarct prior to their 6th birthday21 and 39% by their 18th 
birthday,22 with no evidence that the number of children with new SCI plateaus 
through 20 years of age, Figure 4. Well established risk factors for SCI include low 
baseline hemoglobin,23 particularly before age three years,22  relative hypertension,23 
acute anemia events13,14,22 and evidence of cerebrovascular disease on 
intracranial24,25 and extracranial22 MR angiography (MRA). Unfortunately, the 
presence of multiple SCI risk factors together or independently has not led to accurate 
prediction of SCI. In children with SCD and SCI that do not have either SCA or 
hemoglobin S-β0 thalassemia (entry criteria for the SIT Trial) management should be 
based on an individual basis until large multi-center studies are completed to identify 
optimal management strategies for this population. A more detailed review on the 
natural history, detection, and mimics of SCI in SCD has been recently published.26 
 
Ischemic Lesions of the Brain May Be Temporary or Evolve to Infarcts 
Children with SCA are at increased risk for cerebral lesions likely to be ischemic, but 
not necessarily progressing to infarction. Diffusion weighted imaging (DWI) allows 
detection of acute ischemic events that occurred within the previous ten days. As part 
of the screening protocol to detect SCI in the SIT Trial7 children (n=652) received MRI 
of the brain with DWI.27 In this asymptomatic group of children, the incidence of acute 
silent cerebral ischemic events (ASCIEs) was 47.3 per 100 patient-years (95% CI, 
22.7- 87.2),27 nearly seven times higher than the anticipated incidence of infarct 
recurrence in children with pre-existing SCI,28 but only one of two children with follow-
up MRI of the brain had an infarct. These results strongly suggest that brain ischemia 
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in children with SCA is common and potentially reversible.  Undoubtedly, as MRI 
scanners continue to improve in magnet strength, resulting in improvement in detecting 
cerebral infarcts, the prevalence of ischemic brain injury and SCI will also increase29 
and the epidemiology of both injuries will change. However, MRI of the brain in 
children and adults with SCD cannot replace a thorough neurological examination 
because in the general population, as many as 33% of the individuals with a 
confirmed strokes may have negative DWI MRI of the brain.30  
 
Acute and Chronic Headaches Are Challenging to Manage in SCD 
Headache is one of the most common neurologic symptom in SCD, both acutely31 and 
chronically.32  In acute headache, hemorrhagic stroke (see supplement for images) 
must be considered. In Hines’31 study of acute care visits by children with SCA, 
headache was the chief complaint in 3.8% (102 of 2685). In this group of children 
presenting with acute headaches, 6.9% (7 of 102) had clinically significant CNS 
pathology requiring immediate medical management (3 venous thrombosis, 3 
intracranial hemorrhage, 1 ischemic stroke).31  Acute CNS events associated with 
headaches were more likely with older age, history of stroke, transient ischemic attack, 
or seizure, neurologic symptoms, and focal neurologic findings.31  Unfortunately, no 
clinical features were identified to clearly separate those who did or did not require 
immediate medical management. Neuroimaging was performed in 42.2% of visits, and 
acute CNS events were identified in 16.3% of studies. Distinguishing whether the 
headache is chronic or a new symptom requiring emergent imaging is critical. The 
decision to obtain a MRI of the brain involves eliciting a thorough personal and family 
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history of chronic migrainous symptoms and careful examination of level of 
consciousness, vision and any focal signs. For nocturnal or early morning headaches, 
space-occupying lesion or idiopathic intracranial hypertension33 must be excluded. For 
these reasons, we believe a neurologist should be consulted for severe new onset 
acute headaches.  
 
MRI is not essential for children with SCA and chronic headache, including migraines. 
In the largest retrospective cross-sectional study in children with SCA (n=872), 
recurrent headaches (36.1%) and migraines (15.1%) were both common, but neither 
were associated with SCI.34 Referral to a neurologist is advised for assessment of 
chronic headache and management with diet35, psychological support and prophylactic 
medication (Pizotifen, Propranolol, Topiramate or Valproic acid). We do not 
recommend using triptans for acute migrainous headaches because of the risk of 
cerebral ischemia. Although headache is common, unfortunately, no specific evidence 
based guidelines for management have been developed for SCD.  
 
Hemorrhagic Stroke and Aneurysms Are More Common in Adults 
Intracerebral, intraventricular, subarachnoid (SAH), subdural and extradural 
hemorrhages have all been described in patients with SCD, (see supplement for 
images).36 Hemorrhage, typically subarachnoid, has the highest incidence in 
young adults (20-30 years),3,37  but is not uncommon in children.3  Eleven of 325 
children with SCD (3.4%) with SCD followed at the University of Illinois between 
1975 and 1989 had SAH.38 In a French cohort, 2.8% (7 of 251) of children with 
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SCD had either an intracranial hemorrhage or an un-ruptured aneurysm.39,40  
Risk factors for cerebral hemorrhage are poorly defined, but include hypertension 
associated with the use of corticosteroids36 or phenylephrine41, recent 
transfusion36, splenic sequestration42 and hyper-viscosity associated with higher 
hemoglobin levels.16 
 
Cerebral hemorrhage in adults is commonly related to aneurysm formation (see 
supplement for images).43 In a large study (n=709), the prevalence of aneurysm was 
1.2% and 10.8% in children and adults with SCD, respectively.44  The aneurysms 
which rupture are typically relatively small (2-9 mm),44 and located at the bifurcations 
of major vessels.43,44  
 
Individuals with SCD and intracranial hemorrhage require immediate transfer to a 
tertiary hospital where a multidisciplinary team includes a neurosurgeon with vascular 
interventional neuroradiologist, neurosurgeon, neurologist and hematologist. We are 
unaware of any contra-indication to management of hemorrhage as for the general 
population.44  
 
Extradural and Subdural Intracranial Hemorrhage May Occur Without Trauma 
One of the most under-recognized complications of SCD is extradural or subdural 
hematoma in the absence of significant head trauma,45,46 probably related to 
hypervascular areas of bone47, bone infarction48-50 or venous thrombosis31 (see 
supplement for images). Bony infarction in the orbit may be associated with periosteal 
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hemorrhage and compressive optic neuropathy with risk of visual loss, while 
subgaleal hemorrhage, which may be substantial as there is a large potential space, 
may also occur.51 These lesions are typically managed with appropriate supportive 
care and transfusion, but may require surgery.52 
 
Seizures and Epilepsy Must Be Distinguished and Managed Appropriately  
In the era prior to implementing primary stroke prevention strategy, between 7% and 
10% of individuals with SCD will experience at least one seizure.53,54  In the Jamaican 
cohort Study of Sickle Cell Disease, the five-year cumulative incidence of febrile 
convulsions was 2.2%.54 Even in the context of a febrile or systemic illness, in patients 
with SCD, we recommend brain MRI for first seizure to exclude the possibility of a 
potentially treatable underlying cause, such as arterial ischemic stroke, sinovenous 
thrombosis, reversible posterior encephalopathy syndrome, fat embolism or cerebral 
abscess (see supplement for images). A history of seizures has been associated with 
SCI.55 
 
Epilepsy (recurrent seizures) is two to three times more common than in the general 
population, and is associated with earlier death.54,56 The majority of patients have focal 
abnormality on neuroimaging or electroencephalography57 and cerebrovascular 
disease (see supplement for images).58 Given the high rate of moyamoya in individuals 
with SCD, we do not recommend hyperventilation during electroencephalography 
because of the risk of ischemia.59 
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Central Nervous System Vasculopathy Is Associated with Stroke and SCI 
Stenosis and occlusion of the large arteries of the circle of Willis have been recognized 
in SCD for more than 40 years on pathology60 and contrast arteriography.61 More 
recently less invasive techniques, including Transcranial Doppler ultrasound (TCD) and 
Magnetic Resonance Arteriography (MRA) have been used to detect and follow any 
improvement or progression, but they do not directly visualize the vessel diameter or 
wall and interpretation requires considerable skill. Higher hemoglobin levels provide 
better MRA images. 
 
In the largest study to date (n=516), MRA-defined vasculopathy occurred in 10.3% 
of asymptomatic children with SCA without prior stroke. The presence of MRA 
defined cerebral vasculopathy was associated with SCI; although, the vast 
majority (84%) of children with SCA and SCI did not have MRA defined 
vasculopathy.24  Among children with SCA and strokes, MRA is abnormal in 50-
60% of children.62,63 Among children with SCA and progressive vasculopathy, 
100% had evidence of new cerebral infarct within 5.5 years.62 
 
Despite the routine use of TCD to identify children with SCA at risk for overt strokes, 
several nuances of its use exist. First there are two different methods for imaging 
the intracranial vessels, the imaging and non-imaging techniques.64 Both are 
routinely used with most pediatric radiology departments preferring the imaging 
technique and most research studies using the non-imaging technique. The relative 
benefits and challenges with each technique are discussed in depth elsewhere. 64 
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The most important fact is that the threshold for transfusion used in the non-imaging 
technique is time averaged maximum velocity (TAMV) of 200 cm/sec which is well 
defined and may also be appropriate for the imaging technique,65 while other 
investigators in a clinical trial setting have lowered the threshold of time averaged 
maximum velocity (TAMX in imaging machine ) >185 cm/sec.7 For imaging TCD, until a 
rigorous head to head study is done comparing these two techniques, we prefer the 
more conservative strategy, namely to lower the threshold for treatment to 180 to 185 
cm/sec. 
 
Another subtlety in the use of TCD is that in approximately 10% of the children, 
velocities are low or absent66,67 perhaps related to vasculopathies such as 
moyamoya or extracranial vasculopathy.68  However, MRA define vasculopathy 
without strokes of the brain does not predict future strokes or SCI and cannot be 
reliably applied as a substitute for the lack of a TCD measurement to stratify 
children with SCA into high or low risk future stroke groups  
 
Treatment 
In Children with SCA and Silent Cerebral Infarcts, Regular Blood Transfusion 
Decreases Infarct Recurrence 
No strategy has been established for primary SCI prevention. The only current strategy 
is to prevent infarct recurrence in children with SCI. Despite the importance of 
detecting SCI because of the high rate of future strokes,69 and SCIs,28 as well a drop 
of a Full Scale IQ loss of 5 points70 Figure 5, all of the studies to date have been from 
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high income countries because of the expense of performing MRI of the brain.   
 
The Silent Cerebral Infarct Transfusion (SIT Trial; NCT00072761) was the only trial 
designed to determine whether blood transfusion therapy can prevent progression of 
infarct recurrence (stroke or SCI) in children with SCA and pre-existing SCI. 
Participants included children with SCA (5 to 15 years of age) and SCIs. In the RCT, 
196 children with SCA and SCI were randomly allocated to receive either observation 
(standard therapy) or regular blood transfusion (experimental therapy) for 36 months.  
In participants receiving regular blood transfusion, there was 58% relative risk 
reduction in cerebral infarct recurrence (stroke or new or progressive SCI) when 
compared to the children in the observation arm.7  When compared to observation, the 
benefit of blood transfusion therapy included an improvement of overall quality of life,71 
as well as a statistically significant decrease in the incidence of priapism, new onset 
symptomatic avascular necrosis of the hip, severe vaso-occlusive pain events that 
resulted in hospitalization and acute chest syndrome.7 The number of children with 
SCA and SCI who needed to be transfused to prevent one recurrent infarct was 13.7  
However, the benefit of blood transfusion therapy to prevent infarct recurrence was 
incomplete. Some children in the transfusion therapy arm went on to develop infarct 
recurrence, Figure 6. Thus, the high burden of regular blood transfusion may decrease 
the enthusiasm for infarct recurrence prevention using regular blood transfusion 
therapy in children with pre-existing SCI.  
 
Primary stroke prevention in children in high income countries is successful. 
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The single greatest advance in preventing neurological injury in children with SCA is 
initiating the use of TCD screening to identify a group of children at risk for future 
strokes, primary stroke prevention. The pivotal RCT demonstrated that children with 
elevated TCD measurements > 200 cm/sec receiving regular blood transfusion therapy 
(defined as blood transfusion therapy between three to six weeks with a goal of keeping 
the maximum hemoglobin S level < 30%) when compared to standard therapy 
(observation),will have an approximate 92% relative risk reduction in the rate of overt 
strokes. The number with elevated TCD measurements receiving transfusion therapy to 
prevent one stroke was seven.4  When available, we prefer the use of 
erythrocytapheresis as the approach to regular transfusions because of the lower rate 
of iron accumulation.72 
 
In tertiary care medical centers providing medical care for children with SCA, 
adherence to routine screening of children with SCA using TCD measurements 
coupled with regular blood transfusion therapy has dramatically reduced the rate of 
strokes.  In one large tertiary care center the incidence rate of overt strokes declined a 
log fold before and after the introduction of routine screening with TCD with blood 
transfusion therapy, 0.67 and 0.06 strokes per 100 patient-years, respectively.73 
 
SWiTCH 6 was a secondary stroke prevention trial in children with SCA. The primary 
objective of the trial was to complete a non-inferiority randomized trial of hydroxyurea 
and phlebotomy compared with blood transfusion therapy and chelation for 134 
children with prior stroke who had already undergone at least 18 months of regular 
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transfusion.6  The primary endpoint was a composite of recurrent stroke and liver iron 
concentration (LIC) measured by MRI. There were no strokes in the 66 participants 
randomly allocated to transfusions and chelation (standard therapy), but 7 (10%) in the 
67 participants randomly allocated to hydroxyurea therapy and phlebotomy 
(experimental therapy). The trial was stopped for futility because there was no 
difference in LIC.6  
 
Based in part on consistent findings of studies demonstrating that hydroxyurea therapy 
lowers TCD measurements, Figure 8, the TWiTCH trial (NCT01425307)8 was funded. 
The main objective was a primary stroke prevention trial for children with SCA who 
had received at least 12 months of blood transfusion therapy for TCD velocities above 
200 cm/sec. Children with SCA and prior elevated TCD velocities were randomly 
allocated to continue blood transfusion therapy and chelation (standard therapy (n=61) 
or start hydroxyurea therapy and phlebotomy (experimental therapy (n=60).  
Participants randomly allocated to the hydroxyurea and phlebotomy arm also 
simultaneously received blood transfusion therapy until the hydroxyurea MTD was 
reached (median approximately 6 months overlap). Treatment was scheduled to last 
for 24 months after random allocation, at which point the primary outcome, TCD 
velocity, between the two arms were compared. After the first interim analysis, the trial 
was ended early because the non-inferiority was demonstrated (margin of 15 cm/s).  
 
The management of children with both elevated TCD measurement and MRA defined 
severe cerebral vasculopathy cannot be determined from the TWiTCH trial. 
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Regardless of vasculopathy status of children with elevated TCD measurements, the 
event rate of strokes is very low, <1 in 100 patient years, while receiving blood 
transfusion therapy. 74 Further, in approximately 20% of the children with elevated TCD 
measurements, the TCD measurements will remain elevated several years after 
regular blood transfusion has begun with no evidence that this group is more likely to 
develop future strokes when compared to the group that dropped their TCD 
measurement < 200 cm/sec after blood transfusion therapy. 
 
Given the success of hydroxyurea therapy for primary prevention of strokes and the 
relative low risk to benefit ratio when compared to hematopoietic stem cell transplant 
(HSCT), we would recommend continuing blood transfusion therapy or switching to 
hydroxyurea therapy over HSCT for the perceived high risk group of children with MRA 
defined vasculopathy and elevated TCD measurements. To date there is no evidence 
that TCD measurement in individuals with SCA above 16 years of age is beneficial. In 
the only study to date, Valadi et al. evaluated 110 adults with SCA and controls and did 
not find any values that were elevated.75 
 
Primary Stroke Prevention in Low and Middle Income Countries Is Just Beginning 
No definitive approach has been applied for primary stroke prevention in children with 
SCA living in Africa or India, where the majority of the children born with SCD live. Two 
strategies in Africa have been employed, a standard care protocol using hydroxyurea 
therapy,76  initially using a moderate fixed dose of hydroxyurea therapy of 20 mg/kg 
(SPIN, NCT01801423).77 The feasibility trial included children with SCA between 5 and 
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12 years of age with elevated TCD velocities. The early results indicated that the 
families are willing to participate in a formal trial.77 Further in a short follow up of 
participants and a comparison group (< 18 months), there were initially no 
unwarranted toxicities when compared to a group of children with SCA that were 
screened, had TCD velocities < 200 cm/sec, and were followed prospectively. Perhaps 
most importantly, the early results suggest that children initially started on hydroxyurea 
therapy, instead of blood transfusion therapy, can have significant drops in their TCD 
measurements <200 cm/sec 3 months after starting therapy.77 
 
The essential question for primary stroke prevention in low and middle income 
countries is what dose of hydroxyurea therapy maximizes the benefit and minimizes the 
toxicity. In a setting of high rates of life threatening bacterial infections and malaria, 
treatment with hydroxyurea therapy, a myelosuppressive agent, may result in an 
increased rate of infections or other complications.  Given the low family income in 
urban northern Nigeria, < $700 per year,78 the out of pocket costs of a routine complete 
blood count (CBC), approximately $5, for assessment of hydroxyurea therapy may be 
prohibitive. Thus limiting the financial burden for CBC surveillance for hydroxyurea 
related toxicity may decrease the financial barrier without potentially sacrificing safety. 
Based on the promising early results of the feasibility trial in Kano, Nigeria, SPIN, 
NCT01801423,77 the National Institute of Neurological Diseases and Stroke funded a 
randomized clinical trial to determine the efficacy of 20 mg/kg/day versus 10 mg/kg/day 
of hydroxyurea therapy for primary stroke prevention in children with SCA living in 
Nigeria and Ghana (NCT02560935). For now, in low income countries where TCD 
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screening is initiated for primary stroke prevention and blood transfusion therapy is not 
routinely used, preliminary data suggest that a fixed dose of hydroxyurea therapy at 20 
mg/kg/day is a reasonable starting point for treatment77. 
Blood Transfusion Therapy for Stroke Prevention Is Palliative in High Income 
Countries Standard treatment for secondary stroke prevention is blood transfusion 
therapy. However, even when blood transfusion therapy is initiated, 45% of the 
children with SCA will have infarct recurrence (both stroke and SCI) over a course of 
5.5 years,21 providing evidence that alternative options must be considered for this 
high risk population. Figure 7 depicts the unsatisfactory results of the treatment 
options for secondary infarct recurrence prevention in children with SCA and overt 
strokes. 
Given the evidence that blood transfusion therapy is palliative for secondary stroke 
prevention,62 we believe after an initial stroke, alternative treatment options should be 
considered. Current evidence strongly suggests that HSCT decreases the rate of 
stroke recurrence;79,80 however, most children and adults do not have a viable donor. 
A range of revascularization procedures have become an option for patients with 
internal carotid artery occlusion and moyamoya collaterals.81 Regrettably no RCT has 
been introduced to rigorously assess standard care of regular blood transfusion therapy 
versus neurosurgery and regular blood transfusion therapy.  Given the unknown risk to 
benefit ratio of HSCT and revascularization procedures for secondary stroke 
prevention, we strongly recommend that single or multi-institutional studies be 
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registered with clinicaltrials.gov so we can collectively learn from these variations in 
practices with no clear superior strategy for secondary stroke prevention. 
Strategies Are Just Emerging for Secondary Prevention of Strokes in Low and Middle 
Income Countries 
Given the challenges of routine blood transfusion therapy in low and middle income 
countries, no definitive strategy has emerged for secondary stroke prevention. 
However several investigators in these settings have elected to use hydroxyurea 
therapy as opposed to no therapy. Using pooled analysis comparing blood transfusion 
therapy to hydroxyurea therapy and no therapy, the expected stroke recurrence 
incidence rates were 1.9 (95 CI 1.0-2.9), 3.8 (95% CI 1.9-5.7) and 29.1 (95% CI 19.2-
38.9) events per 100 patient years, respectively.20  A secondary stroke prevention trial 
(NCT pending) is now funded in Nigeria to determine the efficacy of stroke recurrence 
using 20 mg/kg/day versus 10 mg/kg/day of hydroxyurea therapy. The completion of 
the trial is not expected to occur for an additional four years. In the meantime, we 
believe that the available data suggest that treatment with hydroxyurea therapy for 
secondary prevention of strokes is a reasonable alternative when compared to no 
therapy at all.  
Summary 
As a direct result of completed RCTs (STOP, STOP II, SIT, and TWiTCH) in children 
with SCA, a new standard of care has emerged for primary and secondary stroke 
prevention. Based on the preponderance of evidence, the use of hydroxyurea therapy 
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clearly decreases TCD measurements, the main modifiable risk factor for overt strokes. 
Further bolstering the evidence of the impact of hydroxyurea therapy on decreasing 
TCD measurements, the TWiTCH trial has demonstrated the non-inferiority of 
hydroxyurea therapy to blood for primary stroke prevention in children with SCA with 
high TCD velocities without vasculopathy on MRA who have already been transfused for 
a year.  In low and middle income countries, where the majority of children with SCA 
are born, and blood transfusion therapy is not routinely available, primary and 
secondary stroke prevention RCTs are underway to determine the optimal hydroxyurea 
dose that maximizes benefits and limits toxicity, while potentially minimizing laboratory 
surveillance. Very few observational studies and no RCTs in adults with SCD have 
been undertaken for primary and secondary CNS complications (strokes, hemorrhage, 
and aneurysms). Although there have been significant strides in preventing CNS 
complications in the last 25 years, future research will need to focus on adults with SCD 
and individuals with SCD other than SCA, a group still at considerable risk for CNS 
morbidity. 
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Figure 1:  In sub-Saharan African countries and India, where primary prevention is 
not routinely practiced, the pie chart depicts the prevalence of overt strokes and 
silent cerebral infarct in a 1,000 children born with sickle cell anemia followed for 18 
years (based on an assumption that 11%3 will have a stroke and 39% will have silent 
cerebral infarcts prior to the 18th birthday, 21 see text for details). 
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Figure 2. Established risk factors for ischemic injury of the brain in children and 
adults with sickle cell anemia. 
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Figure 3.  The critical relationship between cerebral blood flow and hemoglobin S levels 
in individuals with sickle cell anemia.  
 
The study conducted by Hurlet Jensen et al.15 describes the unique relationship 
between hemoglobin (Hb) and hemoglobin S levels (HbS) and cerebral blood flow 
(CBF) in individuals with sickle cell anemia. As hemoglobin levels increase CBF 
decreases (r= -0.68, p=.006). As hemoglobin S levels increases CBF increases (r=.080, 
p=.0003). In a stepwise multiple regression equation with Hb and HbS, only hemoglobin 
S was accepted and predictive of cerebral blood flow (r=0.70, p=0.01).  
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Figure 4. Prevalence of silent cerebral infarcts in children with sickle cell anemia. 
 
The figure below displays the cumulative prevalence of silent cerebral infarcts in 
children with SCA based on 4 cross-sectional studies 21,22,82-85 and one 
longitudinal study.22 The cumulative prevalence of silent cerebral infarcts strongly 
suggests that the incidence rates of silent cerebral infarcts dose not plateau in 
unselected children and young adults up to 20 years of age with SCA. 
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Figure 5. Meta-analyses for all studies in children with sickle cell anemia that included 
Full Scale IQ for those with and without SCIs. 
 
The meta-analyses include a total of 10 publications comparing the mean difference 
in Full Scale IQ between those children with sickle cell anemia with and without silent 
cerebral infarcts (SCI). The x-axis reflects the mean Full Scale IQ difference between 
those with and without an SCI. The horizontal lines represent the upper and lower 
boundaries of the 95% confidence interval. If the 95% confidence interval overlaps 
zero or crosses the zero threshold then no statistical differences were observed in 
that study. The black and grey diamond represents the results of the fixed and 
random effect models. The edges of the diamonds represent the 95% confidence 
interval of the meta- analyses for the fixed and random effect models (adapted from 
Am J Hematol. 2014  Feb;89(2) :162-7).85 
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Figure 6. A hypothetical cohort of 1,000 children with sickle cell anemia and pre-
existing silent cerebral infarcts followed for five years.  
 
Events are defined as either silent cerebral infarcts or strokes for children with sickle 
cell anemia. The figure depicts the number of children in the cohort with infarct 
recurrence rate (overt and silent cerebral infarct) based on no therapy (4.5 events per 
100 patient years) or regular blood transfusion (2.0 events per 100 patient years).7 To 
provide a frame of reference on the absolute number of children with infarct 
recurrence, we have included the expected number of strokes in 1000 adults without 
sickle cell disease, but with pre-existing untreated atrial fibrillation.  
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Figure 7. A hypothetical cohort of 1000 children with sickle cell anemia and strokes 
followed for five years receiving either no therapy, hydroxyurea therapy, or regular 
blood transfusion therapy.  
 
The figure depicts the number of children in the cohort with stroke recurrence in the no 
treatment group, hydroxyurea therapy group and regular blood transfusion therapy 
group with expected incidence rates of 29.1 (95% CI 19.2-38.9), 3.8 (95% CI 1.9-5.7) 
and 1.9 (95 CI 1.0-2.9) events per 100 patient years, respectively.15 
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Figure 8.  Pooled analysis of the seven studies documenting transcranial 
Doppler measurement before and after hydroxyurea therapy. 
 
The pooled analysis based on the random effect model demonstrating the average drop 
in TCD measurement after starting hydroxyurea therapy of 25 cm/sec. The table also 
includes the observation that the decrease in TCD measurements can be seen as early 
as three months after starting hydroxyurea therapy with a sustained impact of 
hydroxyurea therapy on decreasing TCD measurements for at least 36 months. The 
black diamond represents the results of random effect models. The edges of the 
diamonds represent the 95% confidence interval of the meta-analyses for the random 
effect models. 85 
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